What is rrHBL?


Hepatoblastoma is the most frequent liver cancer affecting infants and children. While cure is possible in approximately 80% of patients, many children progress on initial therapy with refractory disease, having not achieved remission (refractory), or relapse after having achieved remission (relapse). No standards of care exist for such children, as relapsed/refractory hepatoblastoma (rrHBL) has not been formally studied to any significant extent though the international and national cooperative group mechanisms. This registry will fill this gap by prospectively collecting data on children with rrHBL, as well as biological material, to help advance treatment standards and effectiveness, as well as research into novel/better therapies.